Log in

NASDAQ:CUECue Biopharma Stock Price, Forecast & News

-0.16 (-0.80 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $19.86
50-Day Range
MA: $22.34
52-Week Range
Now: $19.86
Volume187,899 shs
Average Volume298,424 shs
Market Capitalization$565.02 million
P/E RatioN/A
Dividend YieldN/A
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CUE



Sales & Book Value

Annual Sales$3.46 million
Book Value$2.37 per share


Net Income$-36,700,000.00
Net Margins-959.08%


Market Cap$565.02 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
-0.16 (-0.80 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

How has Cue Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Cue Biopharma's stock was trading at $15.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CUE shares have increased by 26.4% and is now trading at $19.86.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Cue Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cue Biopharma

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Cue Biopharma

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) released its quarterly earnings data on Tuesday, May, 19th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.15. Cue Biopharma had a negative net margin of 959.08% and a negative return on equity of 103.99%.
View Cue Biopharma's earnings history

What price target have analysts set for CUE?

4 brokers have issued 1 year target prices for Cue Biopharma's shares. Their forecasts range from $30.00 to $33.00. On average, they expect Cue Biopharma's share price to reach $31.25 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price.
View analysts' price targets for Cue Biopharma

Has Cue Biopharma been receiving favorable news coverage?

Press coverage about CUE stock has trended very positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cue Biopharma earned a news impact score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Cue Biopharma

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), Gilead Sciences (GILD), NVIDIA (NVDA), Opko Health (OPK), Canopy Growth (CGC), General Electric (GE), Inovio Pharmaceuticals (INO), KeyCorp (KEY), Novavax (NVAX) and Verizon Communications (VZ).

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the following people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Co-Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sigma Planning Corp (0.19%), Vident Investment Advisory LLC (0.19%), Vident Investment Advisory LLC (0.19%), Swiss National Bank (0.17%), Russell Investments Group Ltd. (0.12%) and Jennison Associates LLC (0.11%). Company insiders that own Cue Biopharma stock include Aaron GL Fletcher, Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar.
View institutional ownership trends for Cue Biopharma

Which major investors are selling Cue Biopharma stock?

CUE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sigma Planning Corp, UBS Group AG, and SG Americas Securities LLC. Company insiders that have sold Cue Biopharma company stock in the last year include Anish Suri, Christopher A Marlett, and Colin Sandercock.
View insider buying and selling activity for Cue Biopharma

Which major investors are buying Cue Biopharma stock?

CUE stock was purchased by a variety of institutional investors in the last quarter, including Vident Investment Advisory LLC, Vident Investment Advisory LLC, Swiss National Bank, Jennison Associates LLC, State Board of Administration of Florida Retirement System, Virtus ETF Advisers LLC, Leap Investments LP, and Rafferty Asset Management LLC. Company insiders that have bought Cue Biopharma stock in the last two years include Aaron GL Fletcher, Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri, and Kerri-Ann Millar.
View insider buying and selling activity for Cue Biopharma

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $19.86.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $565.02 million and generates $3.46 million in revenue each year. The company earns $-36,700,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. Cue Biopharma employs 46 workers across the globe.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is www.cuebiopharma.com.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-949-2680 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.